CA-ASAHI-KASEI
19.4.2022 02:02:07 CEST | Business Wire | Press release
Asahi Kasei Medical concluded an agreement on April 14, 2022 (JST) through a U.S. subsidiary to wholly acquire Bionova Scientific, LLC, a provider of contract process development services and GMP-compliant contract manufacturing services to biopharmaceutical companies, especially those developing next-generation antibody based drugs*.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220417005039/en/
One of the Asahi Kasei Group’s growth engines is the bioprocess business of Asahi Kasei Medical. In addition to the manufacture and sale of Planova™ filters and bioprocess equipment, Asahi Kasei Medical has been proactively expanding this business into the field of biosafety contract testing with the acquisition in 2019 of Austrian viral safety testing services provider Virusure Forschung und Entwicklung GmbH, followed by the 2021 acquisition of U.S.-based mycoplasma testing services provider Bionique Testing Laboratories LLC.
Bionova Scientific’s process development capabilities are particularly highly regarded in the industry, and it has a rich track record regarding complex next-generation antibody drugs, which are typically challenging to manufacture. Its GMP manufacturing facility has state-of-the-art equipment including single-use bioreactors, suited to meet rising demand driven by the expansion of the antibody drug market and a steep increase in the number of biopharmaceuticals entering the clinical pipeline.
Acquiring Bionova Scientific will enable Asahi Kasei Medical to add a biopharmaceutical CDMO (contract development and manufacturing organization) to its bioprocess business. As process development and GMP manufacturing operations are key to the overall success of biopharmaceutical customers’ businesses and the launch of new drugs, being able to offer a broader range of critical know-how driven services to biopharmaceutical customers will allow Asahi Kasei Medical to grow its bioprocess business more rapidly by better serving the industry and by reaching a broader range of customers, including those at the cutting edge of next generation biopharmaceuticals.
Through its provision of innovative and exceptionally reliable products and services, Asahi Kasei Medical aims to contribute to improved safety and efficient manufacture of biotherapeutics, and to further driving the growth of the healthcare sector of the Asahi Kasei Group.
Closing of the acquisition is subject to receipt of necessary regulatory clearances.
* Next generation antibody based drugs differ from conventional antibody based drugs in their degree of complexity and sophistication of mechanism of action, and include examples such as antibody-drug conjugates (ADCs) and bispecific antibodies.
Corporate Profile of Bionova Scientific, LLC |
||
Establishment of current operating form: 2019 |
||
Location: |
Fremont, California, USA |
|
CEO: |
Darren Head |
|
Origins: |
Founded in 2014 as a contract research organization providing biopharmaceutical process development services; the current operating form was established in conjunction with an investment by Great Point Partners in 2019 |
|
Operations: |
Biopharmaceutical manufacturing process development, GMP-compliant manufacturing of current and next-generation antibody drugs |
|
Employees: |
100 (as of April 13, 2022) |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20220417005039/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION14.7.2026 14:00:00 CEST | Press release
Non-arteritic anterior ischemic optic neuropathy (NAION) is a loss of blood flow to the optic nerve which causes spontaneous and rapid vision loss, for which there are currently no FDA-approved treatments. Given the substantial unmet need for effective treatments in NAION, in October 2025, Dompé was awarded a Commissioner’s National Priority Review Voucher (CNPV) by the US FDA to accelerate a potential Biologics License Application for intranasal nerve growth factor (NGF) in NAION. Dompé, a biopharmaceutical company with operations in Italy and the US, announced the first patient has been enrolled in a Phase 3 study of cenegermin-bkbj for the treatment of non-arteritic anterior ischemic neuropathy (NAION). Involving more than 130 centers globally, the Phase 3 trial, “Galassia-NAION-301” is a multicenter, double-blind study comparing cenegermin-bkbj against placebo in improving vision loss caused by NAION. “Our NGF R&D program continues to accelerate with our third clinical study of 202
CE-IVDR Mark for Hologic’s Aptima® HPV Test Expanded to Include Self-Collected Sample Claim in Cervical Cancer Screening14.7.2026 14:00:00 CEST | Press release
New indication in the European Union and the UK offers alternative method of screening especially for women who are not currently participating Hologic, Inc. announced today that its Aptima® HPV Assay received an expanded CE-IVDR marking in the European Union and the UK and is now approved for self-collected vaginal samples using the Aptima Multitest Specimen Collection Kit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714358586/en/ Hologic’s Aptima® HPV Assay and Aptima Multitest Specimen Collection Kit Cervical cancer is the fourth most common cancer in women but is largely preventable through HPV vaccination and regular screening.1 Evidence shows that organized screening and early detection reduces deaths from cervical cancer, with mortality reduction rates in Europe ranging from 41% to 92%.2 However, even in countries with an established cervical screening program, screening participation rates vary widely, from 25%
Cover Genius Raises USD $100M Backed by Vista Credit Partners, Reaching USD $1.9 Billion Valuation as it Advances AI-First Platform and Global Expansion14.7.2026 14:00:00 CEST | Press release
Accelerating the AI roadmap and next era of embedded protection Cover Genius, the global infrastructure for embedded protection, today announced a USD $100M capital raise, backed by Vista Credit Partners, a subsidiary of Vista Equity Partners and strategic financing partner focused on enterprise software. The raise values the business at USD $1.9 billion, advancing a new chapter for the company. Cover Genius operates a B2B2C embedded protection platform that connects 200+ partners with 50+ global insurance carriers to protect over 70 million end customers at the point of sale across travel, retail, ticketing and logistics. Unlike traditional insurers, Cover Genius dynamically adapts product design, pricing, and presentation in real time to match each merchant's unique customer journey and geography mix. “We’ve spent more than a decade building the trust layer the world’s largest digital companies rely on to protect their customers. Today’s raise is about broadening possibilities: movin
Esri to Debut the Power of Where Collection at 2026 Esri User Conference14.7.2026 14:00:00 CEST | Press release
New Titles Expand on Landmark Work to Showcase How GIS Drives Better Decisions Across Water and Land Management Esri will debut the Power of Where Collection at the 2026 Esri User Conference. The collection builds on the 2024 book The Power of Where by Jack Dangermond, extending its ideas into real-world GIS applications. New titles in the collection highlight GIS uses in water forecasting, land records, infrastructure planning, and economic development. The series demonstrates how spatial analysis helps organizations address challenges including sustainability, climate resilience, and governance. Esri, the global leader in location intelligence, will debut the Power of Where Collection at the 2026 Esri User Conference in July. The collection builds on the ideas introduced in The Power of Where: A Geographic Approach to the World's Greatest Challenges, by Esri president Jack Dangermond, published in 2024. The new collection expands these foundational concepts into focused, real-world a
Esri Introduces ArcGIS for ServiceNow, Bringing Location Intelligence into Everyday Enterprise Workflows14.7.2026 14:00:00 CEST | Press release
New Integration Connects Platforms, Enabling Real-Time Mapping Directly Within Existing Systems Esri is launching ArcGIS for ServiceNow, an integration that connects ServiceNow, the AI control tower for business reinvention, with ArcGIS, bringing location intelligence into everyday enterprise workflows. The solution supports organizations across commercial, government, health care, utilities, energy, telecom, and other sectors. Users can visualize incidents, assets, work orders, facilities, and other business data on maps in real time within ServiceNow or ArcGIS, improving decision-making and operational efficiency. The integration eliminates data duplication by enabling seamless data sharing between systems, bridging business records with geographic context. ArcGIS for ServiceNow will debut in beta shortly after Esri User Conference. Esri, the global leader in geographic information system (GIS) technology, has announced ArcGIS for ServiceNow, connecting the two platforms for the firs
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom